Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Operating Income Loss of -$9.95 million for the year ending 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +14.9% in Operating Income Loss from 2024 to 2025.
- This data is from BRAINSTORM CELL THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $868.0 thousand | Q2 2012: -$829.0 thousand | Q3 2012: -$1.15 million | Q1 2013: -$1.08 million | Q2 2013: -$1.50 million | Q3 2013: -$1.08 million | Q1 2014: -$2.11 million | Q2 2014: -$1.29 million | Q3 2014: -$2.43 million | Q1 2015: -$2.21 million | Q2 2015: -$2.36 million | Q3 2015: -$2.57 million | Q1 2016: -$1.81 million | Q2 2016: -$983.0 thousand | Q3 2016: -$1.64 million | Q1 2017: -$1.77 million | Q2 2017: -$1.08 million | Q3 2017: -$2.39 million | Q1 2018: -$2.31 million | Q2 2018: -$3.09 million | Q3 2018: -$3.23 million | Q1 2019: -$4.93 million | Q2 2019: -$4.86 million | Q3 2019: -$5.55 million | Q1 2020: -$8.31 million | Q2 2020: -$7.40 million | Q3 2020: -$4.49 million | Q1 2021: -$6.93 million | Q2 2021: -$6.12 million | Q3 2021: -$5.28 million | Q1 2022: -$5.48 million | Q2 2022: -$7.59 million | Q3 2022: -$6.84 million | Q1 2023: -$5.15 million | Q2 2023: -$5.45 million | Q3 2023: -$6.04 million | Q1 2024: -$2.47 million | Q2 2024: -$2.98 million | Q3 2024: -$3.05 million | Q1 2025: -$3.09 million | Q2 2025: -$2.57 million | Q3 2025: -$2.05 million.
- Over the full 16 years of available data (2010 to 2025), BRAINSTORM CELL THERAPEUTICS INC.'s Operating Income Loss has declined by 514.7%.
- Historical annual values: Fiscal year 2025: -$9.95 million | Fiscal year 2024: -$11.69 million | Fiscal year 2023: -$21.44 million | Fiscal year 2022: -$24.82 million | Fiscal year 2021: -$24.54 million | Fiscal year 2020: -$31.68 million | Fiscal year 2019: -$23.00 million | Fiscal year 2018: -$14.06 million | Fiscal year 2017: -$5.00 million | Fiscal year 2016: -$5.08 million | Fiscal year 2015: -$8.54 million | Fiscal year 2014: -$7.42 million | Fiscal year 2013: -$4.90 million | Fiscal year 2012: -$3.43 million | Fiscal year 2011: -$3.91 million | Fiscal year 2010: $2.40 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: